Results 101 to 110 of about 590 (119)

Mycosis fungoides unmasked by tralokinumab treatment for atopic dermatitis

JAAD Case Reports
Sanah Basrai, BA, Alexander R. Gomez-Lara, BA, BS, Dante Dahabreh, MD, Sebastien De Feraudy, MD, PhD, Eunice Y. Tsai, MD, Patrick E. McCleskey, MD   +5 more
doaj   +1 more source

Long-Term 2-Year Safety and Efficacy of Tralokinumab in Adults With Moderate-to-Severe Atopic Dermatitis: Interim Analysis of the ECZTEND Open-Label Extension Trial

Journal of the American Academy of Dermatology, 2022
Background: Additional long-term treatments are needed for moderate-to-severe atopic dermatitis (AD). An ongoing, open-label, 5-year extension trial, ECZTEND (NCT03587805), assesses tralokinumab plus optional topical corticosteroids in participants from ...
Joshua Corriveau
exaly   +2 more sources

Tralokinumab Therapy for Moderate-to-Severe Atopic Dermatitis: Clinical Outcomes With Targeted IL-13 Inhibition

Allergy: European Journal of Allergy and Clinical Immunology, 2023
Atopic dermatitis (AD) is a chronic, inflammatory, intensely pruritic skin disorder associated with significant patient burden. Interleukin (IL)-13 is a cytokine that acts as a driver of immune dysregulation, skin-barrier dysfunction, and microbiome ...
Mark Boguniewicz, Lawrence F Eichenfield, Eric Simpson   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Review of Tralokinumab in the Treatment of Atopic Dermatitis

Annals of Pharmacotherapy, 2023
Steven R. Feldman, Lindsay Strowd, Rohan Singh   +2 more
exaly  

Tralokinumab Efficacy and Safety, With or Without Topical Corticosteroids, in North American Adults With Moderate-to-Severe Atopic Dermatitis: A Subanalysis of Phase 3 Trials ECZTRA 1, 2, and 3

Dermatology and Therapy, 2022
Neal Bhatia, Melinda Gooderham, Azra Kurbasic   +2 more
exaly  

The Safety and Efficacy of Anti–IL-13 Treatment With Tralokinumab (CAT-354) in Moderate to Severe Asthma: A Systematic Review and Meta-Analysis

Journal of Allergy and Clinical Immunology: in Practice, 2019
Pinhua Pan, Ruoxi He, Chengping Hu
exaly  

Population Pharmacokinetics of Tralokinumab in Adult Subjects With Moderate to Severe Atopic Dermatitis

Clinical Pharmacology in Drug Development, 2022
exaly  

Pharmacokinetics of Tralokinumab in Adolescents With Asthma: Implications for Future Dosing

British Journal of Clinical Pharmacology, 2015
Iwona Stelmach, Piotr Kuna, Meena Jain
exaly  

The Tralokinumab Story: Nothing Is Ever Simple

Journal of Allergy and Clinical Immunology, 2019
Andrea J Apter
exaly  

Targeting IL-13 With Tralokinumab Normalizes Type 2 Inflammation in Atopic Dermatitis Both Early and at 2 Years

Allergy: European Journal of Allergy and Clinical Immunology
Emma Guttman-Yassky, Louise Steffensen
exaly